Foamix Pharmaceuticals (NASDAQ:FOMX) posted its earnings results on Tuesday. The specialty pharmaceutical company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.04), Morningstar.com reports. The firm had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.95 million. Foamix Pharmaceuticals had a negative net margin of 2,062.95% and a negative return on equity of 103.92%.
Foamix Pharmaceuticals stock traded down $0.02 during trading hours on Wednesday, hitting $3.13. The stock had a trading volume of 313,967 shares, compared to its average volume of 332,429. The firm has a market capitalization of $174.52 million, a price-to-earnings ratio of -1.84 and a beta of 1.60. Foamix Pharmaceuticals has a 1-year low of $3.06 and a 1-year high of $7.60.
In other news, insider Matthew T. Wiley bought 13,440 shares of the stock in a transaction on Tuesday, March 5th. The shares were bought at an average price of $3.76 per share, with a total value of $50,534.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 9,311 shares of company stock worth $34,916 in the last three months. 2.95% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the business. Worth Venture Partners LLC acquired a new stake in Foamix Pharmaceuticals in the fourth quarter valued at $48,000. Steward Partners Investment Advisory LLC boosted its stake in shares of Foamix Pharmaceuticals by 29.4% during the first quarter. Steward Partners Investment Advisory LLC now owns 17,155 shares of the specialty pharmaceutical company’s stock valued at $64,000 after acquiring an additional 3,900 shares during the last quarter. Van ECK Associates Corp boosted its stake in shares of Foamix Pharmaceuticals by 75.1% during the fourth quarter. Van ECK Associates Corp now owns 19,752 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 8,474 shares during the last quarter. Credit Suisse AG acquired a new stake in shares of Foamix Pharmaceuticals during the third quarter valued at $194,000. Finally, Federated Investors Inc. PA acquired a new stake in shares of Foamix Pharmaceuticals during the third quarter valued at $287,000. 59.61% of the stock is currently owned by institutional investors.
Several analysts have weighed in on the company. Cantor Fitzgerald reissued a “buy” rating and issued a $15.00 target price on shares of Foamix Pharmaceuticals in a report on Tuesday, April 2nd. Cowen set a $30.00 target price on Foamix Pharmaceuticals and gave the company a “buy” rating in a report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $14.75.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.
Featured Article: Roth IRA